The market of compound penicillin is 24.9 billion, and the injection of triptolide is 62.50%

Antibacterials for whole body use are among the top drugs in the pharmaceutical market, with a wide range of clinical applications and a wide variety of characteristics After the "measures for the administration of clinical application of antibacterial drugs" was formally implemented in China, the rational and standardized use of antibacterial drugs was promoted In 2017, the notice on Further Strengthening the clinical application management of antimicrobial drugs to curb bacterial drug resistance issued by the national health and Family Planning Commission made the magnificent antibiotic market once again contained According to the data of mienei.com, in 2016, the market scale of systemic antibacterials in public medical institutions in China has reached 153.106 billion yuan, among which the market of compound penicillin preparations has reached 24.854 billion yuan, and the compound penicillin β - lactamase inhibitors account for more than 90% of the market share of such drugs Piperacillin sodium, sulbactam sodium and sulbactam sodium are the top three varieties, accounting for 62.50% of the market of compound penicillin Under the trend of limited resistance to the spring tide, the market growth rate shows a steady downward trend   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the growth rate of compound semi synthetic penicillin is explored in systemic anti infective drugs The compound antibiotic preparation mainly consists of β - lactamase inhibitor and cephalosporins or penicillins In the 2017 national medical insurance catalogue, the compound penicillin β - lactamase inhibitor occupied the main position Piperacillin sodium and tazobactam sodium injection, mezlocillin sodium and sulbactam sodium injection, piperacillin sodium and sulbactam sodium injection, amoxicillin sodium and sulbactam sodium injection, ampicillin sodium and sulbactam sodium injection, ticarcillin and clavulanate potassium injection, oral regular release, oral liquid, granules It is the main basic drug of compound antibiotics in China Terminal drug use in public medical institutions of key cities in China is a barometer of the domestic pharmaceutical market, and its online statistics and analysis data represent the overall trend of the domestic pharmaceutical market According to minenet data, in 2016, the sales volume of terminal compound penicillin β lactamase inhibitors in public medical institutions in key cities in China was 1.544 billion yuan, an increase of 2.19% over the previous year According to the newly released data forecast for the first three quarters of 2017, in 2017, the market of terminal compound penicillin β lactamase inhibitors in public medical institutions in key cities in China was 1.583 billion yuan, with the growth rate equal to that of the previous year Among the top 5 clinical drugs, 53.25% were piperacillin sodium and tazobactam sodium, 17.84% were mezlocillin sodium and sulbactam sodium, 17.22% were piperacillin sodium and sulbactam sodium, 8.01% were amoxicillin and clavulanate potassium, and 1.86% were amoxicillin and flucloxacillin (not included in the national medical insurance catalogue), accounting for 1.82% Figure 1: sales volume of terminal compound penicillin of public medical institutions in key cities in China from 2009 to 2017 (unit: 100 million yuan) Figure 2: proportion of terminal compound penicillin of public medical institutions in key cities in China in the first three quarters of 2017 none = "shifumousedownstyle ('shifu_bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> piperacillin sodium and tazobactam sodium injection, the leader of piperacillin sodium and tazobactam sodium injection, is a compound drug composed of broad-spectrum semi synthetic penicillin and β lactamase inhibitor In October 1993, Wyeth's products were approved by FDA to be listed under the trade name of tazocin China approved the import of piperacillin sodium and tazobactam sodium injection from Wyeth in 1996, and the trade name is tezhixing After the successful R & D in 1999, Shenzhen Haibin Pharmaceutical Co., Ltd and Shanghai Xinya Pharmaceutical Co., Ltd were approved for listing According to the CFDA official website database, 26 domestic companies have obtained approval documents for the production of piperacillin sodium tazobactam sodium injection According to the forecast data, in 2017, the amount of piperacillin sodium and tazobactam sodium injection used in public medical institutions in key cities in China was 848 million yuan, an increase of 9.84% over the previous year, with a downward trend compared with the previous year Its Chinese drugs accounted for 88% of the market share, and the original research and import drug special treatment star accounted for 11.27% According to the forecast data, in 2017, the market scale of piperacillin sodium and tazobactam sodium injection in China's public medical institutions will exceed 7 billion Figure 3: sales volume of piperacillin sodium and tazobactam sodium in public medical institutions of key cities in China (unit: 100 million yuan) from 2009 to 2017 Figure 4: competition pattern of piperacillin sodium and tazobactam sodium in public medical institutions of key cities in China in the first three quarters of 2017 Piperacillin sodium tazobactam sodium injection has antibacterial effect on piperacillin sensitive bacteria and β - lactamase resistant bacteria Because tazobactam is a powerful and broad-spectrum β - lactamase inhibitor, the breadth of its inhibition spectrum and the intensity of its inhibition effect are better than that of clavulanate and sulbactam, and the combination of tazobactam and the second generation of semi synthetic penicillin piperacillin has an excellent effect, accounting for half of the compound drugs of broad-spectrum semi synthetic penicillin β - lactamase inhibitor Among the top 5 domestic brands in the first three quarters of 2017, qianglintan of North China Pharmaceutical accounted for 24.12%, fraitazosin of Zhuhai federal accounted for 19.73%, Karen of Hainan general Sanyo accounted for 14.21%, BondA of qilutian and Huishi accounted for 10.61%, and Ruiyang Yongkang of Shandong Ruiyang accounted for 8.13% Domestic drugs occupied the market with the characteristics of high cost performance ratio and multiple product specifications none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> four monopolies of mezlocillin sodium and sulbactam sodium are the mainstream anti bacterial drugs in the hospital market In 2010, sulbactam sodium injection of melocillin sodium of general Sanyo Pharmaceutical Co., Ltd of Hainan was first listed in China, with the trade name of kaveco Subsequently, CFDA approved the listing of products of Shanxi Qianyuan Pharmaceutical Group, Ruiyang pharmaceutical and Suzhou Erye pharmaceutical, forming a pattern of four monopolies Mezlocillin sodium and sulbactam sodium injection entered the normalization in 2014 and maintained a stable growth rate from 2016 to 2017 after the overall growth level of antibiotics declined from 2011 to 2013 According to the forecast data, in 2017, the amount of mezlocillin sodium and sulbactam sodium injection used by public medical institutions in key cities in China was 283 million yuan, an increase of 6.79% compared with the previous year, with a slight decrease in the growth rate compared with the previous year Figure 5: in 2009-2017, the sales volume of mezlocillin sodium and sulbactam sodium, the terminal of public medical institutions in key cities in China (unit: 100 million yuan), of which, Kailin accounts for 36.35% in Shandong Ruiyang, jialotan accounts for 32.65% in Shanxi Qianyuan Pharmaceutical Group, Kaiwei accounts for 28.33% in Hainan general Sanyo, and eryejia accounts for 2.67% in Suzhou Erye It is estimated that the market scale of domestic public medical institutions mezlocillin sodium and sulbactam sodium injection will exceed 3 billion in 2017 none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0,0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> piperacillin sodium and sulbactam sodium into tripod methylpiperacillin sodium and sulbactam sodium injection has the characteristics of broad antibacterial spectrum and strong antibacterial effect, especially for the moderate and severe infection caused by β - lactamase resistant bacteria Piperacillin sodium and sulbactam sodium injection is a new compound antibiotic preparation with intellectual property developed in China According to CFDA data, after the approval of piperacillin sodium and sulbactam sodium injection of China Resources Shuanghe Pharmaceutical Co., Ltd in 2004, seven products of domestic manufacturers were approved for listing Piperacillin sodium and sulbactam sodium injection can effectively solve the problem of drug resistance of piperacillin by using the β - lactamase inhibitor sulbactam It has the characteristics of strong antibacterial activity, wide tissue distribution and small side effects, and is widely used in clinical In 2010, the market sales of piperacillin sodium and sulbactam sodium injection, the terminal of public medical institutions in key cities in China, exceeded 500 million yuan During the period of decline in the overall growth level of antibiotics in 2011, piperacillin sodium and sulbactam sodium injection plummeted, and then it has been at the level of 300 million yuan According to the data of mienei.com, in 2016, the amount of piperacillin sodium and sulbactam sodium injection used by public medical institutions in key cities in China was 313 million yuan, down 7.79% year on year According to the forecast data, in 2017, piperacillin sodium and sulbactam sodium, the terminal of public medical institutions in key cities in China, was 281 million yuan, down 10.26% year on year However, piperacillin sodium and sulbactam sodium injection has a good market in county-level public hospitals, and the overall domestic market has a market scale of nearly 6 billion yuan Figure 6: 2009-2017 sales volume of piperacillin sodium and sulbactam sodium in public medical institutions of key cities in China (unit: 100 million yuan) Figure 7: competition pattern of piperacillin sodium and sulbactam sodium in public medical institutions of key cities in China from January to March 2017 According to the analysis of the competition pattern of the sum of money for piperacillin sodium and sulbactam sodium injection, xinkejun accounts for 29.32% in Wilman, 18.33% in Ruiyang, Shandong, 16.63% in Huarun crane, 10.26% in piperacillin sulbactam, 9.34% in Harbin pharmaceutical, 8.10% in Sichuan Pharmaceutical, 4.19% in Hainan general Kongli, and paishu in Shanghai New Asia Accounting for 3.82% none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; word-wrap: break-word In conclusion, there are more than 300 enterprises in China's penicillin industry, more than 230 enterprises in single penicillin preparation and 150 enterprises in compound penicillin preparation It is estimated that China's penicillin market will reach 45.031 billion yuan in 2020, and the market growth rate of compound penicillin preparation will be slightly higher than that of penicillin overall market